114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
非酒精性脂肪肝对初治慢性乙型肝炎患者基线组织学及 96 周恩替卡韦应答的影响
Authors Gu X, Yang W, Hu Y, Li Y, Zheng L, Jiang B
Received 26 August 2025
Accepted for publication 7 December 2025
Published 23 December 2025 Volume 2025:18 Pages 6817—6824
DOI https://doi.org/10.2147/IDR.S563330
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yan Li
Xiaohui Gu,1,* Weiguang Yang,2,* Yue Hu,3 Yixin Li,4 Liwei Zheng,5 Bei Jiang3
1The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 3Tianjin Second People’s Hospital, Tianjin Institute of Hepatology, Tianjin, People’s Republic of China; 4School of Medical Technology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People’s Republic of China; 5Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA
*These authors contributed equally to this work
Correspondence: Bei Jiang, Tianjin Second People’s Hospital, Tianjin Institute of Hepatology, Tianjin, People’s Republic of China, Email beier0131@163.com Liwei Zheng, Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA, Email liwei.zheng@cuanschutz.edu
Background and Aims: The coexistence of chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) is increasingly common, yet their combined impact on antiviral outcomes remains unclear. This study aimed to compare baseline histopathological features and longitudinal virological responses to entecavir (ETV) therapy in CHB patients with and without NAFLD.
Methods: From October 2014 to January 2022, 299 treatment-naïve CHB patients (130 with NAFLD, 169 without NAFLD) were enrolled in a real-world observational cohort at Tianjin Second People’s Hospital. NAFLD diagnosis was confirmed by liver biopsy and (or) ultrasound examination following AASLD guidelines. Baseline characteristics (histopathology, metabolic profiles, HBV markers) and serial virological outcomes (HBV DNA seroconversion, HBsAg/HBeAg loss rate) were analyzed over 96 weeks of ETV therapy. Statistical comparisons utilized Mann–Whitney U and chi-square tests.
Results: At baseline, NAFLD-comorbid patients exhibited milder hepatic inflammation (G≥ 3: 6.9% vs 17.2%, P =0.022) and fibrosis (S≥ 3: 10.8% vs 17.2%, P =0.020) despite higher metabolic dysregulation (BMI: 24.8 vs 21.5 kg/m2, TG: 1.05 vs 0.89 mmol/L, P < 0.001). While early virological responses (4– 48 weeks) were comparable, NAFLD patients showed significantly lower HBV DNA seroconversion rates at 96 weeks (82.7% vs 92.1%, P =0.038) and persistently reduced HBsAg levels (3.17± 1.07 vs 3.57± 0.67, P = 0.017).
Conclusion: Despite milder baseline histology, NAFLD comorbidity predicts suboptimal 96-week HBV DNA seroconversion and slower HBsAg decline during entecavir therapy, underscoring the need for intensified, integrated metabolic-antiviral management in this cohort.
Keywords: NAFLD, chronic hepatitis B, clinical cohort study, virological response, entecavir
1The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 3Tianjin Second People’s Hospital, Tianjin Institute of Hepatology, Tianjin, People’s Republic of China; 4School of Medical Technology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People’s Republic of China; 5Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA
*These authors contributed equally to this work
Correspondence: Bei Jiang, Tianjin Second People’s Hospital, Tianjin Institute of Hepatology, Tianjin, People’s Republic of China, Email beier0131@163.com Liwei Zheng, Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA, Email liwei.zheng@cuanschutz.edu
Background and Aims: The coexistence of chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) is increasingly common, yet their combined impact on antiviral outcomes remains unclear. This study aimed to compare baseline histopathological features and longitudinal virological responses to entecavir (ETV) therapy in CHB patients with and without NAFLD.
Methods: From October 2014 to January 2022, 299 treatment-naïve CHB patients (130 with NAFLD, 169 without NAFLD) were enrolled in a real-world observational cohort at Tianjin Second People’s Hospital. NAFLD diagnosis was confirmed by liver biopsy and (or) ultrasound examination following AASLD guidelines. Baseline characteristics (histopathology, metabolic profiles, HBV markers) and serial virological outcomes (HBV DNA seroconversion, HBsAg/HBeAg loss rate) were analyzed over 96 weeks of ETV therapy. Statistical comparisons utilized Mann–Whitney U and chi-square tests.
Results: At baseline, NAFLD-comorbid patients exhibited milder hepatic inflammation (G≥ 3: 6.9% vs 17.2%, P =0.022) and fibrosis (S≥ 3: 10.8% vs 17.2%, P =0.020) despite higher metabolic dysregulation (BMI: 24.8 vs 21.5 kg/m2, TG: 1.05 vs 0.89 mmol/L, P < 0.001). While early virological responses (4– 48 weeks) were comparable, NAFLD patients showed significantly lower HBV DNA seroconversion rates at 96 weeks (82.7% vs 92.1%, P =0.038) and persistently reduced HBsAg levels (3.17± 1.07 vs 3.57± 0.67, P = 0.017).
Conclusion: Despite milder baseline histology, NAFLD comorbidity predicts suboptimal 96-week HBV DNA seroconversion and slower HBsAg decline during entecavir therapy, underscoring the need for intensified, integrated metabolic-antiviral management in this cohort.
Keywords: NAFLD, chronic hepatitis B, clinical cohort study, virological response, entecavir